⌘K

17:00:46·268d

SECFilingvia Quantisnow

Sangamo Therapeutics Inc. filed SEC Form 8-K: Leadership Update

ByQuantisnow·Wall Street's wire, on your screen.

SGMO· Sangamo Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

Principal Accounting Officer Jain Nikunj covered exercise/tax liability with 1,919 shares, decreasing direct ownership by 0.81% to 235,292 units (SEC Form 4) (for withholding tax)
Head of Research & Technology Davis Gregory D covered exercise/tax liability with 1,630 shares, decreasing direct ownership by 1% to 113,654 units (SEC Form 4) to cover withholding tax
SVP-CHIEF DEVELOPMENT OFFICER Dubois-Stringfellow Nathalie covered exercise/tax liability with 4,036 shares, decreasing direct ownership by 1% to 328,733 units (SEC Form 4) (for withholding tax)
PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 12,613 shares, decreasing direct ownership by 0.66% to 1,895,043 units (SEC Form 4) (for tax liability)
SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 4,036 shares, decreasing direct ownership by 0.62% to 647,370 units (SEC Form 4) (for withholding tax)